Enger E L, Schwertz D W
J Cardiovasc Nurs. 1989 Aug;3(4):1-15. doi: 10.1097/00005082-198908000-00003.
Myocardial ischemia occurs as a result of an imbalance between tissue oxygen supply and demand. The clinical correlates of the syndrome include classic unstable and Prinzmetal variant angina. Although controversial, it has been postulated that the pathogenesis of unstable angina involves a combination of (1) fixed atherosclerotic coronary artery stenosis, (2) dynamic coronary artery obstruction mediated by coronary vasospasm, and (3) platelet aggregation promoting intracoronary thrombotic occlusion. The authors review evidence to support the conclusion that the interaction of these processes may be mediated by an imbalance in the levels of two eicosanoids, thromboxane A2 (TxA2) and prostacyclin (PGI2), which are responsible for platelet-vascular wall homeostasis. TxA2 is a powerful endogenous vasoconstrictor and promoter of platelet aggregation, whereas PGI2 has diametrically opposed, protective actions. Management and preventive strategies for unstable angina have, therefore, concentrated on the pharmacologic and dietary prohibition of TxA2 activity by agents targeted at inhibiting its synthesis and antagonizing its actions. These agents are discussed and differentiated.
心肌缺血是由于组织氧供与需求之间的失衡所致。该综合征的临床相关表现包括典型的不稳定型心绞痛和变异型心绞痛(普林兹金属心绞痛)。尽管存在争议,但据推测不稳定型心绞痛的发病机制涉及以下因素的综合作用:(1)固定的动脉粥样硬化性冠状动脉狭窄;(2)由冠状动脉痉挛介导的动态冠状动脉阻塞;(3)促进冠状动脉内血栓形成性阻塞的血小板聚集。作者回顾了相关证据,以支持以下结论:这些过程的相互作用可能由两种类花生酸(血栓素A2 (TxA2)和前列环素(PGI2))水平失衡介导,这两种物质负责血小板 - 血管壁的稳态。TxA2是一种强大的内源性血管收缩剂和血小板聚集促进剂,而PGI2具有完全相反的保护作用。因此,不稳定型心绞痛的管理和预防策略集中于通过靶向抑制TxA2合成和拮抗其作用的药物对TxA2活性进行药理学和饮食方面的抑制。本文对这些药物进行了讨论和区分。